Drug Search Results
More Filters [+]

Fluorine f 18 fluorodopa

Alternative Names: fluorine f 18 fluorodopa, fluorodopa, fluorodopa f 18, fluorodopa f-18
Latest Update: 2024-09-20
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: GLUR Antagonist,Decarboxylase Inhibitor,COMT Inhibitor

Novel Mechanism: No

Modality: N/A

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | France | Germany | Hungary | Ireland | Italy | Korea | Luxembourg | Malta | Netherlands | Portugal | Slovenia | Spain | Switzerland | Turkey | United States

Approved Indications: None

Known Adverse Events: None

Company: INSTITUT DE CANCEROLOGIE DE L'OUEST
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Fluorine f 18 fluorodopa

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Brain Cancer|Breast Cancer|Melanoma|Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DOPACER

P2

Active, not recruiting

Melanoma|Breast Cancer|Non-Small-Cell Lung Cancer|Brain Cancer

2023-08-24

Recent News Events

Date

Type

Title